LPRI-424
Drug
Exeltis, USA Inc.
Total Payments
$6.8M
Transactions
1,697
Doctors
2
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2023 | $808,105 | 222 | 0 |
| 2022 | $1.5M | 623 | 0 |
| 2021 | $2.4M | 812 | 0 |
| 2020 | $2.1M | 40 | 2 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $6.8M | 1,697 | 100.0% |
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| A Multicenter, Non-Comparative Trial on the Contraceptive Efficacy, Safety, and Tolerability of LPRI-424, 13 Cycles | Exeltis, USA Inc. | $2.4M | 0 |
| A Pivotal, Multicenter, Non-Comparative Trial on the Contraceptive Efficacy, Safety, Tolerability ofLPRI-424, 13 Cycles | Exeltis, USA Inc. | $2.1M | 2 |
| Pivotal, Multicenter, Non-Comparative Trial on the Contraceptive Efficacy, Safety, Tolerability of LPRI-424, 13 Cycles | Exeltis, USA Inc. | $1.5M | 0 |
| LF111 or Drospirenone Chew vs Non-hormonal Contraceptive Methods on Bone Mineral Density in Adolescent and Adult Women | Exeltis, USA Inc. | $808,105 | 0 |
Ad
Manufacturing Companies
- Exeltis, USA Inc. $6.8M
Product Information
- Type Drug
- Total Payments $6.8M
- Total Doctors 2
- Transactions 1,697
About LPRI-424
LPRI-424 is a drug associated with $6.8M in payments to 2 healthcare providers, recorded across 1,697 transactions in the CMS Open Payments database. The primary manufacturer is Exeltis, USA Inc..
Payment data is available from 2020 to 2023. In 2023, $808,105 was paid across 222 transactions to 0 doctors.
The most common payment nature for LPRI-424 is "Unspecified" ($6.8M, 100.0% of total).
LPRI-424 is associated with 4 research studies, including "A Multicenter, Non-Comparative Trial on the Contraceptive Efficacy, Safety, and Tolerability of LPRI-424, 13 Cycles" ($2.4M).